What is INCY's market cap?

$24.05B, based on the Nov 5 close of $118.01.

What is INCY's P/E ratio?

59.6× trailing-twelve-month earnings of $403.41M.

Does Incyte Genomics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of INCY is sold short?

10.0M shares, 5.9% of float, as of Oct 15, 2026.

What sector is INCY in?

Technology, in the R&D — Physical & Biological Sciences industry.

NASDAQ · INCYTechnologyR&D — Physical & Biological Sciences

Incyte Genomics Inc (INCY)

$118.01−3.94%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$118.01▲ 11.65% in range

Nov 5, 2025Low $90.30 · High $129.93Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Incyte Genomics closed at $118.01 on Nov 5, down 3.94%, 9.2% below its 52-week closing high. Volume of 1.6M shares was 0.83× its 20-day average (close to normal).

Split-adjusted performance: +4.0% over one month, +20.7% over six months, +14.7% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.56B, up 14.0% from a year earlier, with a net margin of -50.4%.

Short interest was 10.0M shares at the Oct 15 settlement (5.9% of float, 5.3 days to cover).

Market cap$24.05B203.8M shares

Revenue · quarter$1.56B+14.0% YoY

Diluted EPS$-3.86−282.9% YoY

P/E · TTM59.6×P/S 4.0×

Net margin-50.4%Gross 93.0%

Dividend yieldNone

52-week range90.30 – 129.93−9.2% from high

Volume1.6M0.83× 20-day avg

Volatility · 60d29.8%Annualised

Short % of float5.9%5.3 days to cover

Net cash$3.82BCash $3.85B

Next earnings—Not scheduled

Split-adjusted performance

1W +1.0%1M +4.0%3M −2.1%6M +20.7%YTD +19.5%1Y +14.7%3Y +118.8%5Y +79.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum30

Revenue growth70

Net margin60

Value (low P/E)—

Size90

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →

Shares short10.0M+0.4% vs prior

Days to cover5.3Settled Oct 15

% of float5.9%

Short vol. 10d70.2%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
INCYIncyte Genomics	$118.01	−3.94%	+20.7%	+14.0%	−50.4%	59.6	$24.05B
MEDPMedpace Holdings	$634.98	−3.32%	+48.1%	+8.5%	19.2%	34.3	$17.76B	Compare
CRLCharles River Laboratories International	$313.02	−4.07%	+72.3%	−2.7%	−0.1%	—	$15.00B	Compare
IQVIQVIA Holdings	$264.88	+0.41%	+48.3%	+8.0%	7.9%	31.3	$43.65B	Compare
ABSIAbsci	$9.39	−10.40%	+63.3%	−46.4%	−10443.4%	—	$1.61B	Compare
OABIOmniAb	$4.83	−6.76%	+228.6%	+78.3%	−393.9%	—	$704.5M	Compare
NRCNRC Health	$25.48	−5.87%	+36.0%	+11.0%	12.3%	88.2	$540.7M	Compare
MXCTMaxCyte	$1.31	−5.76%	+50.3%	−14.5%	−122.0%	—	$135.2M	Compare
IBACIB Acquisition	$10.81	−0.46%	−0.2%	—	—	—	$54.1M	Compare

News about Incyte Genomics

All news →

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research · Oct 26, 2026Neutral INCY or TECH: Which Is the Better Value Stock Right Now?Zacks Investment Research · Sep 30, 2026▲ Positive Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialBenzinga · Jun 9, 2026▲ Positive

Quick answers

What does Incyte Genomics do?: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis.
What is INCY's market cap?: $24.05B, based on the Nov 5 close of $118.01.
What is INCY's P/E ratio?: 59.6× trailing-twelve-month earnings of $403.41M.
Does Incyte Genomics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of INCY is sold short?: 10.0M shares, 5.9% of float, as of Oct 15, 2026.
What sector is INCY in?: Technology, in the R&D — Physical & Biological Sciences industry.

About Incyte Genomics

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

HQ: Wilmington, DE2,844 employeesListed Nov 3, 1993incyte.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology